Skip to main content

Advertisement

SpringerLink
Log in

A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI

  • Clinical Trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Aromatase inhibitor (AI) therapy for estrogen receptor-positive breast cancer is known to induce or enhance musculoskeletal problems. We have previously reported that loss of grip strength is more pronounced in AI-users with extremes in BMI. We here report results from a larger prospective study. Postmenopausal early breast cancer patients scheduled to start AI or tamoxifen therapy were recruited. A functional assessment grip strength test was performed at baseline, 3, 6, and 12 months of therapy. BMI was assessed, and a rheumatologic questionnaire was completed at each visit. 188 patients on an AI and 104 patients on tamoxifen were enrolled. 74 % of AI-users reported new/worsened musculoskeletal complaints compared with 37 % in the tamoxifen group. This was translated in a larger grip strength decrease in patients experiencing AI-induced pain opposed to patients without new/worsened complaints (p = 0.0002). 15 % of AI-users discontinued therapy due to musculoskeletal symptoms, who were characterized by a larger grip strength reduction versus adherent patients (p = 0.0107). Young age (p = 0.0135), taxane-based chemotherapy (p = 0.0223), and baseline VAS score >4 (p = 0.0155) were predictors for AI-related musculoskeletal pain. In addition, a quadratic trend of BMI with grip strength change (p = 0.0090) and probability of discontinuation was observed (p = 0.0424). Musculoskeletal events were a substantial problem in AI-treated patients and an important reason for treatment discontinuation. The decrease in grip strength was larger in AI- than in tamoxifen-users, with a more pronounced change in symptomatic patients. The inverse relationship between BMI extremes and grip strength change was confirmed in this large group of AI-patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Petit T, Dufour P, Tannock I (2011) A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer. Endocr Relat Cancer 18(3):R79–R89

    Article  CAS  PubMed  Google Scholar 

  2. Thürlimann B, Keshaviah A, Coates A, Mouridsen H, Mauriac L, Forbes J, Paridaens R, Castiglione-Gertsch M, Gelber R, Rabaglio M et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353(26):2747–2757

    Article  PubMed  Google Scholar 

  3. Crew K, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman D (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25(25):3877–3883

    Article  PubMed  Google Scholar 

  4. Henry N, Giles J, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, Lemler S, Shahverdi K, Powers P et al (2008) Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111(2):365–372

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Coleman R, Bolten W, Lansdown M, Dale S, Jackisch C, Merkel D, Maass N, Hadji P (2008) Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 34(3):275–282

    Article  CAS  PubMed  Google Scholar 

  6. Morales L, Pans S, Verschueren K, Van Calster B, Paridaens R, Westhovens R, Timmerman D, De Smet L, Vergote I, Christiaens M et al (2008) Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 26(19):3147–3152

    Article  PubMed  Google Scholar 

  7. Lintermans A, Van Calster B, Van Hoydonck M, Pans S, Verhaeghe J (2011) Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis generating findings for its pathogenesis. Ann Oncol 22(8):1763–1769

    Article  CAS  PubMed  Google Scholar 

  8. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ, members P (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24(9):2206–2223

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Grunfeld EA, Hunter MS, Sikka P, Mittal S (2005) Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59(1):97–102

    Article  PubMed  Google Scholar 

  10. von Blanckenburg P, Schuricht F, Albert US, Rief W, Nestoriuc Y (2013) Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trial. BMC Cancer 13:426

    Article  Google Scholar 

  11. Swenson KK, Nissen MJ, Henly SJ, Maybon L, Pupkes J, Zwicky K, Tsai ML, Shapiro AC (2013) Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in women with breast cancer receiving aromatase inhibitors. Oncol Nurs Forum 40(6):549–557

    Article  PubMed  Google Scholar 

  12. Singer O, Cigler T, Moore AB, Levine AB, Hentel K, Belfi L, Do HT, Mandl LA (2012) Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study. Arthritis Care Res (Hoboken) 64(12):1910–1918

    Article  CAS  Google Scholar 

  13. Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S et al (2009) Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101(23):1624–1632

    Article  PubMed Central  PubMed  Google Scholar 

  14. Irwin ML, Cartmel B, Gross C (2013) Randomized trial of exercise vs. usual care on aromatase inhibitor-associated arthralgias in women with breast cancer: the hormones and physical exercise (HOPE) study. In: San Antonio Breast Cancer Symposium: 2013, San Antonio, 2013

  15. Khan QJ, Kimler BF, Reddy PS, Sharma P, Klemp JR, Fabian CJ (2012) Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms and fatigue in women with breast cancer starting adjuvant letrozole: the VITAL trial. In: ASCO: 2012, Chicago, 2012

  16. Henry NL, Banerjee M, Wicha M, Van Poznak C, Smerage JB, Schott AF, Griggs JJ, Hayes DF (2011) Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. Cancer 117(24):5469–5475

    Article  CAS  PubMed  Google Scholar 

  17. Mao JJ, Xie SX, Farrar JT, Stricker CT, Bowman MA, Bruner D, DeMichele A (2014) A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use. Eur J Cancer 50(2):267–276

    Article  CAS  PubMed  Google Scholar 

  18. Greenlee H, Crew KD, Shao T, Kranwinkel G, Kalinsky K, Maurer M, Brafman L, Insel B, Tsai WY, Hershman DL (2013) Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer. Support Care Cancer 21(4):1077–1087

    Article  PubMed  Google Scholar 

  19. Kubo M, Onishi H, Kuroki S, Okido M, Shimada K, Yokohata K, Umeda S, Ogawa T, Tanaka M, Katano M (2012) Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer. Anticancer Res 32(6):2331–2336

    CAS  PubMed  Google Scholar 

  20. Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA et al (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30(9):936–942

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Shi Q, Giordano SH, Lu H, Saleeba AK, Malveaux D, Cleeland CS (2013) Anastrozole-associated joint pain and other symptoms in patients with breast cancer. J Pain 14(3):290–296

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Park JY, Lee SK, Bae SY, Kim J, Kim MK, Kil WH, Lee JE, Nam SJ (2013) Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors. J Korean Surg Soc 85(5):205–211

    Article  PubMed Central  PubMed  Google Scholar 

  23. Chim K, Xie SX, Stricker CT, Li QS, Gross R, Farrar JT, DeMichele A, Mao JJ (2013) Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors. BMC Cancer 13:401

    Article  PubMed Central  PubMed  Google Scholar 

  24. Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes J, Bianco A, Buzdar A, Group AT (2008) Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 9(9):866–872

    Article  PubMed  Google Scholar 

  25. Hirokaga K, Egawa C, Takao S (2013) Chemotherapy, but not body mass index has impact on joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. In: San Antonio Breast Cancer Symposium: 2013, San Antonio, 2013

  26. Muslimani A, Spiro T, Chaudhry A, Taylor H, Jaiyesimi I, Daw H (2009) Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms? Clin Breast Cancer 9(1):34–38

    Article  CAS  PubMed  Google Scholar 

  27. Mao JJ, Stricker C, Bruner D, Xie S, Bowman MA, Farrar JT, Greene BT, DeMichele A (2009) Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 115(16):3631–3639

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Kanematsu M, Morimoto M, Honda J, Nagao T, Nakagawa M, Takahashi M, Tangoku A, Sasa M (2011) The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia. BMC Cancer 11:436

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Laroche F, Coste J, Medkour T, Cottu PH, Pierga JY, Lotz JP, Beerblock K, Tournigand C, Declèves X, de Cremoux P et al (2014) Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study. J Pain 15(3):293–303

    Article  CAS  PubMed  Google Scholar 

  30. Chlebowski RT, Kim JS, Haque R (2014) Adherence to endocrine therapy in breast cancer adjuvant and prevention settings. Cancer Prev Res (Phila) 7(4):378–387

Download references

Funding

This work was supported by the Stichting Emmanuel van der Schueren, the scientific partner of the Vlaamse Liga tegen Kanker.

Conflict of interest

The authors have declared no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Oncology, KU Leuven, Herestraat 49, 3000, Louvain, Belgium

    A. Lintermans, K. Van Asten, H. Wildiers, R. Paridaens, A. Smeets, K. Leunen, M. R. Christiaens & P. Neven

  2. Multidisciplinary Breast Center, University Hospitals Leuven, Louvain, Belgium

    H. Wildiers, R. Paridaens, C. Weltens, A. Smeets, E. Van Limbergen, K. Leunen, M. R. Christiaens & P. Neven

  3. General Medical Oncology, University Hospitals Leuven, Louvain, Belgium

    H. Wildiers & R. Paridaens

  4. Electrical Engineering (ESAT-SISTA), KU Leuven, Louvain, Belgium

    A. Laenen

  5. Radiotherapy, University Hospitals Leuven, Louvain, Belgium

    C. Weltens & E. Van Limbergen

  6. Laboratory of Clinical and Experiment Endocrinology, KU Leuven, Louvain, Belgium

    J. Verhaeghe & D. Vanderschueren

  7. Gynecology, University Hospitals Leuven, Louvain, Belgium

    J. Verhaeghe, K. Leunen & P. Neven

  8. Laboratory Medicine, University Hospitals Leuven, Louvain, Belgium

    D. Vanderschueren

  9. Surgical Oncology, University Hospitals Leuven, Louvain, Belgium

    A. Smeets & M. R. Christiaens

Authors
  1. A. Lintermans
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Van Asten
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Wildiers
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Laenen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Paridaens
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Weltens
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Verhaeghe
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D. Vanderschueren
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A. Smeets
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. E. Van Limbergen
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. K. Leunen
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M. R. Christiaens
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. P. Neven
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Lintermans.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lintermans, A., Van Asten, K., Wildiers, H. et al. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI. Breast Cancer Res Treat 146, 109–116 (2014). https://doi.org/10.1007/s10549-014-2986-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-014-2986-7

Keywords

Search

Navigation